April 4th 2025
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, discusses the etiologies of hepatocellular carcinoma (HCC) and how clinicians can tailor treatment for patients with varied levels of liver function.
Watch
Dr Ari Green on Promising Remyelination Therapies and Patient Outcomes in MS
April 12th 2024Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.
Watch
Study Urges Personalized Care to Boost Quality of Life in Patients With MM
April 11th 2024Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
Read More
Expert Analysis Reveals Critical Insights for Optimizing Care in LA-NSCLC
April 11th 2024Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
Read More
Study: Children With SCD Not Found to Abuse Opioids Long-Term
April 10th 2024A retrospective cohort study assessed patterns of opioid use in children with sickle cell disease (SCD) following their initial opioid prescription for pain management, finding that concerning patterns of opioid abuse did not develop.
Read More
Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment
April 9th 2024The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Read More
Health Equity and Access Weekly Roundup: April 8, 2024
April 8th 2024The Center on Health Equity and Access covered the burden faced by caregivers, transgender health care, pre-exposure prophylaxis uptake, disparities in postpartum mental health care, and cost-related medication nonadherence among patients with chronic obstructive pulmonary disease.
Read More
Dr Raajit Rampal Discusses Disease Modification and Emerging Therapies in Polycythemia Vera
April 7th 2024Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.
Watch
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
April 4th 2024Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Read More